CSF biomarkers: pinpointing Alzheimer pathogenesis - PubMed (original) (raw)
Review
CSF biomarkers: pinpointing Alzheimer pathogenesis
Niklas Mattsson et al. Ann N Y Acad Sci. 2009 Oct.
Abstract
Intense research during the last decades has resulted in an unprecedented accumulation of knowledge regarding the pathogenesis of Alzheimer's disease. Primarily, the focus has been directed toward amyloid and tau pathology and their relations to synaptic and neuronal loss. However, as the complexity of the disease becomes increasingly evident, the importance of other factors, such as inflammation, oxidative stress, and mitochondrial dysfunction, grow apparent. Here, we review available CSF biomarkers for these pathological processes. We also consider their usability in clinical practice and in clinical trials.
Similar articles
- Failure of biomarkers in clinical trials of Alzheimer's disease: blaming the messenger?
Quinn J, Clark CM. Quinn J, et al. J Alzheimers Dis. 2009;18(1):103-4. doi: 10.3233/JAD-2009-1128. J Alzheimers Dis. 2009. PMID: 19625755 Review. No abstract available. - Alzheimer's biomarker initiative hits its stride.
Miller G. Miller G. Science. 2009 Oct 16;326(5951):386-9. doi: 10.1126/science.326_386. Science. 2009. PMID: 19833956 No abstract available. - CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM. Kester MI, et al. Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271. Neurology. 2009. PMID: 19858456 - Biomarkers in Alzheimer's disease.
Lovestone S. Lovestone S. J Nutr Health Aging. 2006 Mar-Apr;10(2):118-22. J Nutr Health Aging. 2006. PMID: 16554945 No abstract available. - [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A, Roche S, Lehmann S. Gabelle A, et al. Rev Neurol (Paris). 2009 Mar;165(3):213-22. doi: 10.1016/j.neurol.2008.05.004. Epub 2008 Jul 7. Rev Neurol (Paris). 2009. PMID: 18808768 Review. French.
Cited by
- The future of blood-based biomarkers for Alzheimer's disease.
Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW; Blood-Based Biomarker Interest Group. Henriksen K, et al. Alzheimers Dement. 2014 Jan;10(1):115-31. doi: 10.1016/j.jalz.2013.01.013. Epub 2013 Jul 11. Alzheimers Dement. 2014. PMID: 23850333 Free PMC article. Review. - Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments.
Castro P, Zaman S, Holland A. Castro P, et al. J Neurol. 2017 Apr;264(4):804-813. doi: 10.1007/s00415-016-8308-8. Epub 2016 Oct 24. J Neurol. 2017. PMID: 27778163 Free PMC article. Review. - Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.
Wu L, Rosa-Neto P, Gauthier S. Wu L, et al. Mol Diagn Ther. 2011 Dec 1;15(6):313-25. doi: 10.1007/BF03256467. Mol Diagn Ther. 2011. PMID: 22188635 - Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Wikler EM, Blendon RJ, Benson JM. Wikler EM, et al. Alzheimers Res Ther. 2013 Sep 6;5(5):43. doi: 10.1186/alzrt206. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 24010759 Free PMC article. - Assessment and treatment of pain in people with dementia.
Corbett A, Husebo B, Malcangio M, Staniland A, Cohen-Mansfield J, Aarsland D, Ballard C. Corbett A, et al. Nat Rev Neurol. 2012 Apr 10;8(5):264-74. doi: 10.1038/nrneurol.2012.53. Nat Rev Neurol. 2012. PMID: 22487749 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical